Roche, Novartis Lose French Court Battle Over Off-Label Use Of Avastin In AMD

Roche and Novartis have been unsuccessful in their attempt to stop the French authorities using Avastin off label in wet AMD for financial reasons.

Rejected
A French court has rejected an attempt to stop Avastin being reimbursed for AMD

France’s highest administrative court, the Conseil d’Etat, has rejected attempts by Novartis and Roche to stop the use of Roche’s anticancer Avastin (bevacizumab) for the treatment of wet AMD, an unapproved indication, in place of Novartis’ Lucentis (ranibizumab), which is authorized for the condition but is much more expensive.

The court rejected the companies’ request to annul a “temporary use authorization” (RTU) issued by the regulatory body,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from France

More from Europe